TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Acceptability of program tool
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of subjects with high risk score (≥8)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRD-negative complete remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with PJP infection
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of total vitamin B12 in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: STAI questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of sperm motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Treadmill Walking Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in children's symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in reported symptoms and distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Presence or absence of anatomical structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of acute radiation pneumonitis
Endpoint domain: Adverse events/effects
Primary endpoint: Neuropathy severity assessed by Total Neuropathy Score (TNS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time-weighted Sum of Pain Intensity Differences for 12 hours post-dose (SPID 12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of treatment emergent adverse events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of treatment emergent clinically significant abnormal laboratory assessments
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of Deep Brain Stimulation (DBS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients with fracture union
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: patient satisfaction questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Back pain function scale changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-mile run-time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Shoulder Instability Episodes (Subluxation and Dislocations)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Presence of donor specific antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: incidences of ≥ grade 3 treatment-related toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Gene Expression (mRNA levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gene Expression (Protein levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytotoxic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anti-cancer efficiency of drug-loaded nanoparticles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MEDL score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TMD prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of all-cause hospitalisations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Quality-of-life adjusted life years
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of intraoperative body movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative chest tube removal time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change of 6-minute walk distance (6MWD) from baseline to Months 6, 12, and 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of NT-proBNP from baseline to Months 6, 12, and 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of patients with initial cure at Day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Portal vein diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Family Burden
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Positive and Negative Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Recommended Perinatal Care Components Received
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: AUC24/MIC target attainment of vancomycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of diagnostic profitability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of Chronic Obstructive Pulmonary Disease (COPD)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in cortisol pre-post condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Interleukin-6 (IL6) pre-post condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: High Frequency (HF) Heart Rate Variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Warwick-Edinburgh Mental Wellbeing scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Treatment Persistence Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Relative dose intensity (RDI) of chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change of PVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Organ biodistribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PET uptake of tracer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Days abstinent in the past 30 days
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Sexual Assertiveness From Baseline to 3 Month Followup
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Resistance Tactics From Baseline to 3 Month Follow up
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Dating Self-Protection Against Rape From Baseline to 3 Month Follow up
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: MRD-negativity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in fasting glucagon-like peptide-1 (GLP1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in insulin sensitivity (IS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in 24 hour systolic blood pressure (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in indexed left ventricular mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rating of Effort
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Levels of surfactant protein D (SPD) in bronchial lining fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of CCL18 in bronchial lining fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of CXCL13 in bronchial lining fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of periostin in bronchial lining fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gestational age change in lung vibroacoustics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in nodule size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Modified gut microbiota composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sleepiness Sensitivity KSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue Sensitivity POMS-F
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: On task psycho-physical stress NASA-TLX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success in learning self-management of the pessary
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Percentage of participants who reported Serious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants who reported Serious Adverse Drug Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants who reported unexpected Adverse Events/Adverse Drug Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants who reported known Adverse Drug Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants who reported non-serious Adverse Event/Adverse Drug Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants who reported events related to important identified risks
Endpoint domain: Adverse events/effects
Primary endpoint: Primary fistula closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in indirect markers of muscle damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Aronia metabolites in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aronia metabolites in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time-weighted MAP below 65 mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Patient Scar Assessment Scale (PSAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observer Scar Assessment Scale (OSAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean ΔmGFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Perioperative reliability of VX1+ in detecting electrograms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of serum thyroglobulin (Tg) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of serum thyroglobulin antibody (TgAb) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change of serum calcium level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of serum alkaline phosphatase (ALP) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of tumor-background ratio on bone scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Average Menstrual Symptom Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of Nursing Assistant Task - Nasal Swab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Completion of Nursing Assistant Task - Obtain Patient Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of Nursing Assistant Task - Obtain Vital Signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of Nursing Assistant Task - Attach Telemetry Stickers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Completion of Nursing Assistant Task - Place Nasal Cannula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: total keratometric astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abulafia-Koch formula total corneal astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Barrett toric calculator total corneal astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Theoretical dose of CBD received by the breastfed child over 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: participant retention rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: buprenorphine adherent rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: linkage rate to addiction treatment programs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Modified Anxiety Dental Scale (MADS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Total Per Member Per Month (PMPM) Healthcare Costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cumulative proportion of patients with distal radius fracture surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in urine albumin/creatinine ratio (UACR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Adjusted Mean HbA1c(%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relative rate of closure of a tunneling or undermining feature
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum tolerated dose (MTD) of STI-3031
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained biochemical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained sonographic remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sustained endoscopic remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with serious adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with CTCAE 5.0 grade 3 or higher adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects who prematurely withdrew from the study due to adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline to the end of the study period in participants with SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Chimeric status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of PROM with GBS infection
Endpoint domain: Adverse events/effects
Primary endpoint: Salivary viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of treated patients with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor response by imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of RSV infection in ECOPD patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: sensitivity of Neuropad to detect DAN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: specificity of Neuropad to detect DAN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: accuracy of Neuropad to detect DAN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Occurrence of maternal fever during labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of free from death and heart failure related hospitalizations
Endpoint domain: Mortality/survival
Primary endpoint: Joint Contact Stress-Time Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in inflammatory age (iAge®) scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurodevelopmental function (adaptive behaviour score)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Hematologic remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of Imaging Agent-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical and biological evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior knee pain scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Effectiveness of pharmacological activation of HIF-1alpha in counteracting sarcopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reintubation within 48 hours after extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Forced Expiratory Volume in the first second
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in tumour features
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Post procedure adverse events and complication
Endpoint domain: Adverse events/effects
Primary endpoint: bimanual Speed/Accuracy Trade-off (bi-SAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bimanual Coordination factor (bi-CO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bi-Force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microcirculation evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of infections after liver transplantation
Endpoint domain: Adverse events/effects
Primary endpoint: Overall acceptability to patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall acceptability to primary care providers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall acceptability to clinic staff
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Canadian Occupational Performance Measure (COPM) Trained Goal Performance
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: NeuroQoL Cognitive Function Short Form
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Changes in FVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in health-related Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in overall health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in care-related QoL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in perceived well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Antimicrobial resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Patient self-reported disposal of prescription opioids
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Adherence to Gluten-Free Diet (GFD)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Monthly Itch Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24 Hour Visual Analogue Scale (VAS) Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monocyte production of reactive oxygen species before vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Monocyte production of reactive oxygen species after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Relapse or abstinence after detoxification
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of detection of atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anticoagulant use for prevention of stroke
Endpoint domain: Adverse events/effects
Primary endpoint: sensitivity and specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Reporting one or More Treatment-emergent Adverse Events (TEAEs) and Per Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Days alive and out of hospital at 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Weight gain by BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of CMD in patients with HFpEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Morning Systolic and Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Evening Systolic and Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in The Fremantle Back Awareness Questionnaire (FreBAQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning